Evidence map›Paper›PMID 40695989›Full record

Articlenpj antimicrobials and resistance2025

Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins.

Ivan Sugrue, Carolin Ade, Paula M O'Connor, Jan-Martin Daniel, Paolo Innocenti, Nico Kirsch, Nathaniel I Martin, Günther Weindl, Colin Hill, Tanja Schneider and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj antimicrobials and resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molecular action of NZ2114, a superior plectasin derivative.npj antimicrobials and resistance · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ivan Sugrue *APC Microbiome Ireland, University College Cork, Cork, Ireland.
Carolin Ade *Institute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Paula M O'ConnorTeagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.
Jan-Martin DanielInstitute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Paolo InnocentiBiological Chemistry Group, Institute of Biology, Leiden University, Leiden, The Netherlands.
Nico KirschDepartment of Pharmacology and Toxicology, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
Nathaniel I MartinBiological Chemistry Group, Institute of Biology, Leiden University, Leiden, The Netherlands.
Günther WeindlDepartment of Pharmacology and Toxicology, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
Colin HillAPC Microbiome Ireland, University College Cork, Cork, Ireland.
Tanja SchneiderInstitute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn, Bonn, Germany.
R Paul RossAPC Microbiome Ireland, University College Cork, Cork, Ireland. p.ross@ucc.ie.

Funding

Deutsches Zentrum für Infektionsforschung GRK2873 (494832089)European Union (ERC) 101054719
6 · The paper itself

Abstract

Antimicrobial peptides are defense molecules found across all domains of life holding promise for developing therapies against drug-resistant pathogens. Actifensin, from Actinomyces ruminicola DPC7226, exhibits potent activity against gram-positive bacteria and shares structural similarities with eukaryotic defensins. This study characterized actifensin's mechanism of action and therapeutic potential. The findings revealed that actifensin inhibits peptidoglycan synthesis by binding lipid II (Kd = 30 ± 20 nM). Unlike defensins, it also binds lipid I (Kd = 24 ± 27 nM) without significant difference, suggesting the N-acetyl glucosamine moiety of lipid II is not required for complexation. Membrane disruption was not observed with DiSC

Identifiers

PMID40695989
PMCPMC12284004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.